140 related articles for article (PubMed ID: 10492066)
1. The role of ifosfamide in the treatment of lymphomas.
Hagemeister FB
Leuk Lymphoma; 1999 Aug; 34(5-6):433-41. PubMed ID: 10492066
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. The role of ifosfamide in cytoreduction, stem cell mobilization and high-dose therapy in relapsed/refractory malignant lymphomas.
Hagemeister FB; Diehl V
Eur J Haematol Suppl; 2001 Jul; 64():1-2. PubMed ID: 11486394
[No Abstract] [Full Text] [Related]
4. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
King K; Younes A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):14-22. PubMed ID: 10697039
[TBL] [Abstract][Full Text] [Related]
6. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Vose JM
Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
8. The role of ifosfamide in the treatment of relapsed and refractory lymphoma.
Reiser M; Bredenfeld H; Engert A; Diehl V
Eur J Haematol Suppl; 2001 Jul; 64():37-40. PubMed ID: 11486400
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide in the treatment of lymphoma.
Coiffier B
Semin Oncol; 1996 Jun; 23(3 Suppl 7):2-7. PubMed ID: 8711498
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide in the treatment of non-Hodgkin's lymphoma.
Pohlman B
Semin Oncol; 1996 Jun; 23(3 Suppl 6):27-32. PubMed ID: 8677445
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide in hematological malignancies of adults.
Rodeghiero F; Elice F
Oncology; 2003; 65 Suppl 2():85-93. PubMed ID: 14586156
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience.
Hagemeister FB; Donato M
Eur J Haematol Suppl; 2001 Jul; 64():8-13. PubMed ID: 11486405
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide in the treatment of germ cell tumors.
Nichols CR
Semin Oncol; 1996 Jun; 23(3 Suppl 6):65-73. PubMed ID: 8677452
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide in the treatment of soft tissue sarcomas.
Connelly EF; Budd GT
Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide in the treatment of breast cancer.
Overmoyer BA
Semin Oncol; 1996 Jun; 23(3 Suppl 6):38-41. PubMed ID: 8677447
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide in the treatment of bladder cancer.
Roth BJ
Semin Oncol; 1996 Jun; 23(3 Suppl 6):50-5. PubMed ID: 8677450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
